Lifeboat Foundation

Zero-emissions long-distance aviation is absolutely possible… Provided you’re not in a hurry. Solar Airship One will take 20 days to fly all the way around the equator, some 40,000 km (~25,000 miles), in a single zero-emissions hop.

The 151-m (495-ft)-long airship will have its entire upper surface covered in solar film – some 4,800 square meters (51,700 sq ft) of it, or about nine-tenths of an NFL football field for those of you who prefer the standard units.

Continue reading “Solar-powered airship will circle the world non-stop without fuel” »

(BRLS), formerly known as Life Extension Foundation, Inc., is one of the world’s leading providers of financial support for otherwise unfunded research in the areas of cryobiology, interventive gerontology and cryonics. During the last decade alone, BRLS awarded more than $100 million in grants to highly-specialized cryogenic research organizations.

BRLS is exempt from taxation under Internal Revenue Service code Section 501©(4)¹, and is operated exclusively to promote social welfare through scientific research and education. BRLS was founded in 1977, and since then, we have awarded hundreds of grants to scientists throughout the United States who are personally committed to our mission. These dedicated professionals take extraordinary steps to make their research as cost-effective as possible. We are careful to commit our research dollars to projects that are difficult or impossible to fund through government and institutional grants or other sources.

Nonprofit organization, whose goal is the extension of the healthy human lifespan

Biomedical Research and Longevity Society, Inc. (BRLS), formerly known as Life Extension Foundation, Inc., is one of the world’s leading providers of financial support for otherwise unfunded research in the areas of cryobiology, interventive gerontology and cryonics. During the last decade alone, BRLS awarded more than $100 million in grants to highly-specialized cryogenic research organizations.

Visit website: https://www.brlsociety.org/.

With better food preservation and factories that are more precise along with more upgrades to the global supply line we could even eliminate poverty with the food that is wasted.

It is estimated that 1.3 billion metric tons of food are lost or wasted annually, translating to a financial loss of $1 trillion (USD) per year. And without significant changes, this problem is expected to grow to 2.1 billion metric tons and $1.5 trillion by 2030.

Staggering as these numbers might be, they do not take into account the hidden costs of food production, including labor, storage and salvage or the costs related to customer dissatisfaction, lost opportunities, and inventory/stocking level imprecision.

Continue reading “Food Waste Costs the World’s Economy $1T Each Year” »

AN EXTRAORDINARY WAVE OF PROGRESS against cancer has occurred in the United States over the past three decades. From its peak in 1991, cancer mortality has declined by more than a third. Smoking cessation, human papillomavirus (HPV) vaccination, improved cancer screening and better cancer treatments are poised to push cancer deaths even lower. In 2022, this prompted President Joe Biden to reignite the Cancer Moonshot launched in 2016 with a goal of reducing cancer death rates even further—cutting them in half over the next 25 years.

With growing success in the treatment of many cancers has come a reexamination of the profound impact cancer treatment has on those with the disease. A cancer survivor faces a plethora of physical, emotional, social and financial challenges. Surgery, radiation therapy, chemotherapy and immunotherapy are all plagued by short-term toxicities and longer-term complications that can dominate life during and after cancer treatment and impinge upon its quality.

Fortunately, the same detailed knowledge of cancer genes and gene programs that has led to spectacular advances in cancer treatment may also improve cancer survivorship. Molecular profiling of individual cancers is now commonly used in cancer treatment planning. Breast cancer, long known to be a highly heterogeneous collection of diseases, provides a compelling example. For many years, testing breast tumor tissues for the presence of the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) has been essential to steering women with breast cancer toward or away from endocrine therapies or agents like Herceptin (trastuzumab) that bind to HER2. Newer molecular profiling tools—including Oncotype DX, MammaPrint, Breast Cancer Index, EndoPredict and the Prosigna Breast Cancer Prognostic Gene Signature Assay—have further refined and individualized breast cancer treatment decision-making.

A study led by the University of Oxford has used the power of machine learning to overcome a key challenge affecting quantum devices. For the first time, the findings reveal a way to close the “reality gap”: the difference between predicted and observed behavior from quantum devices. The results have been published in Physical Review X.

Quantum computing could supercharge a wealth of applications, from climate modeling and financial forecasting to drug discovery and artificial intelligence. But this will require effective ways to scale and combine individual quantum devices (also called qubits). A major barrier against this is inherent variability, where even apparently identical units exhibit different behaviors.

Functional variability is presumed to be caused by nanoscale imperfections in the materials from which quantum devices are made. Since there is no way to measure these directly, this internal disorder cannot be captured in simulations, leading to the gap in predicted and observed outcomes.

Over the past twenty years, many companies, including Google, Microsoft, and IBM, have invested in quantum computing development. Investors have contributed over $5 billion to this cause. The aim is to use quantum physics properties to process information in ways that traditional computers cannot. Quantum computing could impact various fields, including drug discovery, cryptography, finance, and supply-chain logistics. However, the excitement around this technology has led to a mix of claims, making it hard to gauge the actual progress.

The main challenge in developing quantum computers is managing the ‘noise’ that can interfere with these sensitive systems. Quantum systems can be disrupted by disturbances like stray photons from heat, random signals from nearby electronics, or physical vibrations. This noise can cause errors or stop a quantum computation. Regardless of the processor size or the technology’s potential uses, a quantum computer will not surpass a classical computer unless the noise is controlled.

For a while, researchers thought they might have to tolerate some noise in their quantum systems, at least temporarily. They looked for applications that could still work effectively with this constraint. However, recent theoretical and experimental advances suggest that the noise issue might soon be resolved. A mix of hardware and software strategies is showing potential for reducing and correcting quantum errors. Earl Campbell, vice president of quantum science at Riverlane, a UK-based quantum computing company, believes there is growing evidence to be hopeful about quantum computing’s future.

Super Humanity — This documentary examines breakthroughs in neuroscience and technology. Imagine a future where the human brain and artificial intelligence connect.

Super Humanity (2019)
Director: Ruth Chao.
Writers: Ruth Chao, Paula Cons, Alphonse de la Puente.
Genre: Documentary, Sci-Fi.
Country: Portugal, Spain.
Language: English.
Release Date: December 27, 2019 (Spain)

Continue reading “Super Humanity | Breakthroughs in Neuroscience” »

An alarmingly large portion of the world’s business and finance systems run on COBOL, and only a small community of programmers know it. IBM thinks Watson can help, but it’s not guaranteed.